Date: Wednesday, August 14th, 2019
Time: 8:00 am - 4:30 pm EST
Location: Dante Alighieri Society of Massachusetts, 41 Hampshire Street, Cambridge, MA, 02139
Join us for a day of transformative research with implications for drug discovery and clinical practice 
across the field of immuno-oncology in the heart of Cambridge, MA at the Dante Alighieri Society of Massachusetts. Come listen to your colleagues in pharma, biotech and academia discuss how their research is breaking down the barriers to novel oncology treatment options.
Register now to hold your spot for our complimentary event! Limited space available.
Speakers from various organizations including:
- Parul Agnihotri, PhD, Genocea Biosciences
- Lorella Di Donato, PhD, Caprion Biosciences
- Johanna K. Kaufmann, PhD, TESARO a GSK Company
- Shashi Murthy, PhD, Flaskworks
- Julia Schüler, PhD, DVM, Charles River Laboratories
- Russel Weiner, PhD, the Bill & Melinda Gates Medical Research Institute
AGENDA
| 8:00 - 8:30 am | Registration and breakfast |
| 8:30 – 9:00 am | Welcome and Introductions Cathie G. Miller, PhD, Director of Product Marketing, Personalized Medicine, BioIVT |
| 9:00 – 10:00 am | Innovative Approaches for Neoantigen-Based T Cell Therapy Manufacturing Shashi Murthy, PhD, Founder & CTO, Flaskworks |
| 10:00 – 11:00 am | PDX Models of Solid Cancer Express Distinct Cytokine Profiles Relating to Their Tumor Infiltrating Lymphocyte Landscape Julia Schüler, PhD, DVM, Research Director, Charles River Labs |
| 11:00 am – 12:00 pm | A GCLP Workflow for the Measurement of Protein Biomarkers in FFPE Tissue Samples by Mass Spectrometry Lorella Di Donato, PhD, Senior Vice-President and Chief Operating Officer, Caprion Biosciences |
| 12:00 – 1:00 pm | Lunch |
| 1:00 – 2:00 pm | Beyond PD-1 Blockade: Combination Immune Checkpoint Inhibition Engages Multiple Mechanisms of Action Johanna K. Kaufmann, PhD, Associate Director, Immuno-Oncology, Tesaro, a GSK Company |
| 2:00 – 2:15 pm | Break, Coffee and refreshments will be served |
| 2:15 – 3:15 pm | ATLAS™ Technology Improves Neoantigen Selection for Personalized Cancer Vaccines Parul Agnihotri, PhD, Scientist I, Translational Immunology, Genocea Biosciences |
| 3:15 – 4:15 pm |
Successful Implementation of Global Biomarker Strategies: |
| 4:15 – 4:30 pm | Closing Remarks Cathie G. Miller, PhD, Director of Product Marketing, Personalized Medicine, BioIVT |
